News

 

EASTBOUND ADVANCES CGMP AT NEW SHANGYU SITE

 

Dr Leo Lin joins management as head of Quality

Shangyu, China (August 6, 2010)

Eastbound Pharma Ltd. (“Eastbound”) has taken another step in preparing their new Shangyu site for current Good Manufacturing Practice (cGMP) operations in 2010. Eastbound announces the July appointment of Dr Leo Weiyang Lin as Vice President of Quality, Regulatory Affairs and EHS. The appointment comes on the heels of the recent expansion of Eastbound to install new cGMP manufacturing at the Shangyu site. Investment plans are already underway to raise the compliance of that site to the ICH Q7A guidelines and Dr Lin will be instrumental in the design and validation of those improvements.

Dr Lin comes to Eastbound from Nanning Maple Leaf Pharmaceuticals, Ltd a wholly owned Canadian pharmaceutical company. “Leo brings Eastbound practical hands‐on experience in cGMP operation and will drive our effort to raise the standard and get Shangyu certified” says Michael Zhang, Chief Operating Officer of Eastbound. “Leo will bring to Eastbound 10 years experience in innovative drug development, preparation and maintenance of Drug Master Files and Certificates of Compliance in major markets.”

Dr Lin received his MSc in Medicinal Chemistry and PhD in Biochemistry and Molecular Biology at the University of Manitoba and post‐doctoral work at Hong Kong University of Science and Technology. His previous positions include R&D director at WEX pharmaceuticals in Vancouver and VP/CSO, Executive VP/CSO and General Manager/CSO at Nanning Maple Leaf Pharmaceutical Co., Ltd, where he was responsible for the API manufacturing, product development and cGMP compliance.

Eastbound Pharma Ltd. is a leading provider of custom process development and contract manufacturing of ingredients used in pharmaceutical manufacturing. Operations include the Eastbound Shanghai Institute where more than 50 chemists and engineers provide custom process development. Dafeng Eastbound Fine Chemicals is a manufacturing division of Eastbound that provides scale‐up and commercial manufacturing capability for non‐cGMP intermediates and fine chemicals. The Shangyu site of Eastbound Pharma Ltd. produces intermediates and APIs requiring cGMP manufacturing capability. Eastbound companies employ over 300 people and offer nearly 400 cubic meters reactor capacity in China to Western pharmaceutical companies.